Cited 2 times in
Cefepime Versus Cefepime Plus Amikacin as an Initial Antibiotic Choice for Pediatric Cancer Patients With Febrile Neutropenia in an Era of Increasing Cefepime Resistance
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강지만 | - |
dc.date.accessioned | 2020-12-01T17:54:20Z | - |
dc.date.available | 2020-12-01T17:54:20Z | - |
dc.date.issued | 2020-10 | - |
dc.identifier.issn | 0891-3668 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/180503 | - |
dc.description.abstract | Background: We investigated the treatment outcomes before and after the addition of amikacin to cefepime monotherapy as an initial empirical antibiotic treatment in pediatric cancer patients with febrile neutropenia. Methods: This was a retrospective historical cohort study. The subjects were pediatric cancer patients who visited the emergency room at the Samsung Medical Center, Seoul, Korea, due to chemotherapy-induced febrile neutropenia, between January 2011 and December 2016. Since September 2014, the empirical antimicrobial treatment regimen for febrile neutropenia was changed from high-dose cefepime monotherapy to combination therapy of adding a single dose of amikacin. Results: Two hundred twenty-five bacteremia episodes in 164 patients were reported during the study period. Bacteremia caused by cefepime-resistant Gram-negative bacteria was observed in 16% of patients before September 2014 and in 21% of the patients after September 2014 (P = 0.331). Use of appropriate empirical antibiotic treatments increased from 62% to 83% following addition of amikacin to cefepime treatment (P = 0.003). The duration of fever was shorter in the cefepime plus amikacin group than in the cefepime group (22 vs. 34 hours, P = 0.014); however, rates of septic shock and pediatric intensive care unit hospitalizations were not significantly different between the 2 groups (septic shock, both 7%, P = 0.436; pediatric intensive care unit 3% vs. 1%, P = 0.647). Conclusions: We observed no additional benefit of amikacin addition to high-dose cefepime monotherapy. Therefore, adding amikacin to cefepime monotherapy in conditions where cefepime-resistant Gram-negative bacteremia amounts to 20% or less may not be justified. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Williams & Wilkins | - |
dc.relation.isPartOf | PEDIATRIC INFECTIOUS DISEASE JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Cefepime Versus Cefepime Plus Amikacin as an Initial Antibiotic Choice for Pediatric Cancer Patients With Febrile Neutropenia in an Era of Increasing Cefepime Resistance | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pediatrics (소아청소년과학교실) | - |
dc.contributor.googleauthor | Na Hee Lee | - |
dc.contributor.googleauthor | Ji-Man Kang | - |
dc.contributor.googleauthor | Ji Won Lee | - |
dc.contributor.googleauthor | Hee Jae Huh | - |
dc.contributor.googleauthor | Nam Yong Lee | - |
dc.contributor.googleauthor | Keon Hee Yoo | - |
dc.contributor.googleauthor | Ki Woong Sung | - |
dc.contributor.googleauthor | Hong Hoe Koo | - |
dc.contributor.googleauthor | Yae-Jean Kim | - |
dc.identifier.doi | 10.1097/INF.0000000000002751 | - |
dc.contributor.localId | A05720 | - |
dc.relation.journalcode | J02487 | - |
dc.identifier.eissn | 1532-0987 | - |
dc.identifier.pmid | 32453199 | - |
dc.identifier.url | https://journals.lww.com/pidj/Fulltext/2020/10000/Cefepime_Versus_Cefepime_Plus_Amikacin_as_an.14.aspx | - |
dc.contributor.alternativeName | Kang, Ji-Man | - |
dc.contributor.affiliatedAuthor | 강지만 | - |
dc.citation.volume | 39 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 931 | - |
dc.citation.endPage | 936 | - |
dc.identifier.bibliographicCitation | PEDIATRIC INFECTIOUS DISEASE JOURNAL, Vol.39(10) : 931-936, 2020-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.